Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novozymes has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges.
Subscribe to our email newsletter
Under the terms of the agreement, Gene Bridges has licensed the Red/ET technology to Novozymes for the purpose of genetically engineering recombinant micro-organisms for use in industrial applications.
Tim Zeppenfeld, business development manager of Gene Bridges, said: “We are very pleased to add Novozymes to the list of major industrial biotechnology companies using Red/ET. Recombineering is the technology of choice in metabolic engineering and is used worldwide in industry and academia.”